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THE RESISTANCE of hypoxic tumour
cells to radiotherapy may be a common
cause of local failure, for there is good
evidence that hypoxic cells exist in nearly
all human tumours which are treated.
Among the methods which have been
introduced to overcome this problem, the
chemical radiosensitizers are the most
recently developed (Adams et al., 1976).
There is considerable interest in them for
they have great potential for wide use in
radiotherapy (Lancet, 1978).
The first drug to be tested clinically for
this purpose was metronidazole in 1973,
shortly followed in 1974 by misonidazole
(Ro 07-582, MISO) a much more effective
drug in laboratory studies (Fowler et al.,
1976). Now many clinical trials are under
way with this compound in Europe, the
United States, Canada, South Africa,
Australia, New Zealand and Japan.
In the early stages of testing MISO, as
the dose was increased, the drug proved
to be neurotoxic, producing encephalo-
pathy and peripheral neuropathy (Dische
et al., 1977). A dose limit of 12 g/m2 to be
given over a period of not less than 17
days has now been generally accepted.
With this dose limitation, most cases of
peripheral neuropathy are mild and tran-
sient, but there is still an incidence of
-30°%, and an occasional case of more
severe toxicity (Dische et al., 1979). The
dose may achieve a sensitization of
hypoxic cells by a factor of 1-3-1-6
(Fowler et al., 1976) but this must be com-
pared with a factor of 2-5-3 which is
required to bring sensitization back to the
level of that of oxic cells. Nevertheless
there is an expectation that some of the
current trials will show benefit with the
use of the drug.
A considerable effort is currently being
made to develop new compounds which
may lead to greater radiosensitization. A
direct relationship has been demonstrated
between the lipophilicity of radiosensi-
tizing nitroimidazoles and neurotoxicity
(Conroy, 1980). High tumour/brain con-
centration ratios have been obtained with
drugs of relatively low lipophilicity
(Brown & Lee, 1980). The alternative
approach is to develop a compound with
a shorter half-life in the plasma, for it has
been shown in clinical as well as in animal
studies that the area under the time curve
of plasma concentration can be directly
related to the incidence of neurotoxicity
(Dische et al., 1979). The i.v. route has
been considered as a potentially superior
one, particularly with the use of some of
the less lipophilic compounds (White et
al., 1980); but this will reduce clinical use
because of the practical problems in-
volved with the administration of i.v.
preparations, particularly when a patient
may receive 20-30 radiation treatments in
a course lasting 4-6 weeks.
Desmethylmisonidazole (the Roche ex-
perimental drug Ro 05-9963, DESMISO)
is the first metabolite of MISO, and it has
been detected in the plasma and urine
after MISO has been administered (Flock-
hart et al., 1978a). As a radiosensitizer itS. DISCHE ElT AL.
is abouit eqtual in efficiency to MISO
(Fowler et al., 1976). The drug, however,
combines a lower lipophilicity (the octanol/
water partition coefficients are MISO 0 43,
DESMISO 0 11) with a shorter half-life
in dogs and mice (White & Workman,
1980; Stratford, 1980, personal com-
munication).
Some studies with this compouind have,
however, suggested similar toxicity to
MISO (Roche Products Ltd, 1979). Other
studies in nmice and dogs have showvn less
toxicity for DESMISO (Conroy, 1980;
Sheldon, 1979, personal communication).
Further, recent work with rats at the
Institute of Cancer Research using tests
of both co-ordination and enzyme analysis
ofperipheral nerves has showvn much lower
toxicity with DESMISO than with MISO
(Adams, 1980 personal communication).
A prediction of poor absorption of
DESMISO when given orally has led to
plans for i.v. administration (White &
Workman, 1980; Brown & Lee, 1980). A
direct testing of DESMISO in man
seemed to us the only way to determine
the plasma concentration and its time
course after administration. Through the
kind cooperation of Dr Hassall, Dr
Pearson and Dr Lenox-Smith of Roche
Products Ltd, a supply of DESMISO was
made available to uIs for a small study of
normal volunteers.
The drug was dissolved in water imme-
diately before administration to 3 male
subjects. On 15 January 1980, 0 5 g of
DESMISO/m2 was given under near-
fasting conditions to all 3. One week later
1 g of DESMISO/m2 was administered to
2 subjects and finally, a week later, a dose
of 0-5 g/m2 of MISO was administered to
all 3. Nitroimidazole concentrations in
blood and urine were determined by high-
performance liquid chromatography
(Dische et al., 1979).
The plasma concentrations measured in
the 3 subjects are shown (Figure). The
concentrations recorded after administra-
tion of MISO are of total nitroimidazoles.
The small concentration of DESMISO
is thus added to the MISO measured, as
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Fic.. Desmethylmisonidazole (DESAIISO)
was a(lministerecl to 3 male subjects (PA,
SD, JFF). The total plasma eoneentrations
of nitroima(lazole are shown ( ig/ml) for
eachi subject after doses of:
0-5 g DESMISO/m2 (V)
1-0 g DESMISO/m2 (A)
05 g MISO/m2 (D)
1)rug half lives (L): v A z2
PA 5-3 9 0
SD 6-4 6-3 117
JF'F 5-4 6-4 10-4
they are equally effective radiosensitizers.
When we compare the plasma concen-
trations in the 3 subjects given identical
amounts of DESMISO and MISO we find
that after 1-2 h the average DESMISO
concentrations were 85, 82 and 7200
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of the total nitroimidazoles when MISO
was given. Subsequently the DESMISO
levels fell more rapidly, with half lives of
5-4. 6-4 and 5-3 h compared with 10-4, 11-7
and 9 h for MISO (calculated by least-
squares fit). Doubling the dose of DES-
MISO appears to double the plasma con-
centrations, as previously observed with
MISO (Dische et al., 1979).
Examination of the urine collected in
the 24h period after the first administra-
tion of DESMISO showed that 44, 55
and 59% of the dose was excreted. After
the second administration, when the dose
was doubled, 50 and 520/ was excreted.
In contrast, during the same period after
administration of MISO, 31. 23 and
34% was excreted, either unchanged or as
DESMISO.
The relationship of plasma concentra-
tion to time with DESMISO should lead to
satisfactory tumour concentrations(Flock-
hart et al., 1978b). Because of the more
rapid clearance, normal tissue exposure
will be reduced to half that with MISO.
In addition, we can expect a reduction of
the concentration in nervous tissue, due
to lowerlipophilicity.
The results suggest that DESMISO
might prove a more efficient drug for oral
use as an hypoxic cell sensitizer in man
than MISO. Drug concentrations several
times greater than those achieved with
MISO may be attained and the incidence
of neurotoxicity may be reduced. A
clinical study to determine drug levels in
human tumours and in cerebrospinal fluid
is now indicated.
We wish to tliank tlie, Medieal Researcii Counell
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